Abbott Laboratories(ABT) Stock Research - Grey Stern Research
Loading...

Abbott Laboratories (ABT) Stock Analysis

$134.80 (1.09%)

ABT Financial Performance


Use the table below to view Abbott Laboratories's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $134.80 -
52 Week Low $99.71 -
52 Week High $141.23 -
Market Cap $234.5 Billion 4/6
Gross Margin 55% 6/6
Profit Margin 84% 1/6
EBITDA margin 27% 3/6
Q4 - 2024 Revenue $11.0 Billion 5/6
Q4 - 2024 Earnings $9.2 Billion 1/6
Q4 - 2024 Free Cash Flow $2.1 Billion 4/6
Trailing 4 Quarters Revenue $42.0 Billion 5/6
Trailing 4 Quarters Earnings $13.4 Billion 2/6
Quarterly Earnings Growth 479% 1/6
Annual Earnings Growth 127% 2/6
Quarterly Revenue Growth 7% 3/6
Annual Revenue Growth 3% 5/6
Cash On Hand $7.6 Billion 3/6
Short Term Debt $1.5 Billion 5/6
Long Term Debt $13.5 Billion 5/6

Abbott Laboratories Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Abbott Laboratories's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 17.50 5/6
PS 5.59 3/6
PB 4.90 5/6
PC 30.79 3/6
Liabilities to Equity 0.70 5/6
ROA 0.16 1/6
ROE 0.28 3/6
Current Ratio 2.43 1/6
Quick Ratio 0.24 1/6
Long Term Debt to Equity 0.28 5/6
Debt to Equity 0.32 5/6
Burn Rate -0.92 5/6
Cash to Cap 0.03 3/6
CCR 0.23 4/6
EV to EBITDA 80.94 3/6
EV to Revenue 5.77 3/6

Company Details

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

CEO: Mr. Robert Ford

Website: https://www.abbott.com

Address: 100 Abbott Park Rd ABBOTT PARK, ILLINOIS

Exchange: New York Stock Exchange

Industry: Medical Devices

Abbott Laboratories Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Abbott Laboratories. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Bristol-Myers Squibb Company BMY $95.1 Billion
AbbVie Inc. ABBV $325.1 Billion
Johnson & Johnson JNJ $364.7 Billion
Medtronic plc MDT $110.9 Billion
Eli Lilly and Company LLY $717.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ABT Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 11.0 Billion $9.2 Billion
Q3 2024 $ 10.6 Billion $1.6 Billion
Q2 2024 $ 10.4 Billion $1.3 Billion
Q1 2024 $ 10.0 Billion $1.2 Billion
Q4 2023 $ 10.2 Billion $1.6 Billion
Q3 2023 $ 10.1 Billion $1.4 Billion
Q2 2023 $ 10.0 Billion $1.4 Billion
Q1 2023 $ 9.7 Billion $1.3 Billion

View All

ABT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $7.6 Billion $81.4 Billion $15.0 Billion $47.9 Billion
Q3 2024 $0 $0 $0 $0
Q2 2024 $7.0 Billion $73.0 Billion $14.8 Billion $39.6 Billion
Q1 2024 $6.3 Billion $72.5 Billion $14.6 Billion $39.0 Billion
Q4 2023 $7.0 Billion $0 $0 $37.7 Billion
Q3 2023 $6.7 Billion $72.1 Billion $15.5 Billion $71.9 Billion
Q2 2023 $7.8 Billion $73.4 Billion $16.8 Billion $37.2 Billion
Q1 2023 $9.9 Billion $74.4 Billion $16.8 Billion $74.2 Billion

View All

ABT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 $2.1 Billion -$720.0 Million $58.0 Million
Q3 2024 $0 $0 $0
Q2 2024 $1.4 Billion -$533.0 Million $703.0 Million
Q1 2024 $627.0 Million -$398.0 Million -$612.0 Million
Q4 2023 $0 $0 $0
Q3 2023 $0 $0 $0
Q2 2023 $696.0 Million -$507.0 Million -$1.3 Billion
Q1 2023 $763.0 Million -$380.0 Million -$721.0 Million

View All